Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
PRECIGEN, INC. | Director | Common Stock | 503K | $720K | $1.43 | Mar 14, 2024 | Direct |
Theravance Biopharma, Inc. | Director | Ordinary Shares | 80.6K | $696K | $8.64 | May 8, 2024 | Direct |
PRECIGEN, INC. | Director | Restricted Stock Units | 87.4K | $125K | $1.43 | Mar 14, 2024 | Direct |
ImmunoGen, Inc. | Director | Common Stock | 0 | $0 | $29.30 | Feb 12, 2024 | Direct |
ImmunoGen, Inc. | Director | Deferred Share Unit | 0 | $0 | $29.30 | Feb 12, 2024 | Direct |
ImmunoGen, Inc. | Director | Restricted Stock Unit | 0 | $0 | $29.30 | Feb 12, 2024 | Direct |
PRECIGEN, INC. | Director | Option to Purchase Common Stock (Right to Buy) | 102K | Mar 14, 2024 | Direct | ||
Theravance Biopharma, Inc. | Director | Share Option (Right to Buy) | 23.6K | May 8, 2024 | Direct | ||
Praxis Precision Medicines, Inc. | Director | Stock Option (Right to Buy) | 8.57K | Jun 5, 2024 | Direct | ||
ImmunoGen, Inc. | Director | Stock Option (Right to Buy) | 0 | $4.56 | Feb 12, 2024 | Direct | |
Kinnate Biopharma Inc. | Director | Stock Option (right to buy) | 0 | Apr 3, 2024 | Direct |